Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (306)	12/23/2002 5:50:28 AM
From: dalroi	Read Replies (1) \| Respond to of 625

whaw, its cleaning up the mess in 1 time laywers became to expensive ??? LOL, realy like catg handing out licenses :-) the more ab developped by catg licenses the more ..........

To: nigel bates who wrote (306)	12/23/2002 6:28:02 AM
From: nigel bates	Respond to of 625

Note no mention of royalty payments in the Xoma deal. A little colour from the FT - Peter Chambre, who recently took over as chief executive of CAT, said: "We have previously stated that we were prepared to work with MorphoSys to settle the actions on the right terms and this agreement puts an end to the distraction to both parties caused by the litigation. In addition, in reaching this agreement CAT shareholders will benefit from the future growth of MorphoSys' business." Last week CAT settle a long-running litigation with Crucell, its Dutch rival, over the technology they used to develop new drugs. Crucell, which has developed a technique very similar to that used by CAT, has agreed to pay a licence fee as well as royalties to CAT on any drugs it develops. Both settlements mark a change in strategy at CAT, where Peter Chambre recently took over as chief executive. The company has been locked in legal fights with Crucell and MorphoSys of Germany for several years. But recently Mr Chambre said he would rather settle on fair terms to build a larger number of antibody drugs in the market and on which the group earns a royalty. ...